U.S. markets open in 3 hours 57 minutes
  • S&P Futures

    3,225.50
    -5.75 (-0.18%)
     
  • Dow Futures

    26,641.00
    -44.00 (-0.16%)
     
  • Nasdaq Futures

    10,774.00
    -55.00 (-0.51%)
     
  • Russell 2000 Futures

    1,450.90
    +4.20 (+0.29%)
     
  • Crude Oil

    39.63
    -0.30 (-0.75%)
     
  • Gold

    1,855.00
    -13.40 (-0.72%)
     
  • Silver

    22.24
    -0.87 (-3.77%)
     
  • EUR/USD

    1.1641
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    0.6760
    0.0000 (0.00%)
     
  • Vix

    28.99
    +2.13 (+7.93%)
     
  • GBP/USD

    1.2727
    +0.0002 (+0.01%)
     
  • USD/JPY

    105.3760
    +0.0440 (+0.04%)
     
  • BTC-USD

    10,313.90
    +64.43 (+0.63%)
     
  • CMC Crypto 200

    217.51
    +3.54 (+1.66%)
     
  • FTSE 100

    5,859.80
    -39.46 (-0.67%)
     
  • Nikkei 225

    23,087.82
    -258.67 (-1.11%)
     

Recap: WAVE Life Sciences Q1 Earnings

Benzinga Insights

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 1.47% over the past year to ($1.38), which missed the estimate of ($1.20).

Revenue of $4,161,000 rose by 37.51% from the same period last year, which missed the estimate of $6,050,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 11, 2020

View more earnings on WVE

Time: 07:03 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/evfwy3gr

Price Action

Company's 52-week high was at $39.98

52-week low: $6.61

Price action over last quarter: down 2.45%

Company Description

WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.